[
  {
    "ts": "2026-02-19T01:15:49+00:00",
    "headline": "Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation",
    "summary": "Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting. Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5%...",
    "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5afe4d13-0e39-3acb-8ce2-f12c29e9edad",
      "content": {
        "id": "5afe4d13-0e39-3acb-8ce2-f12c29e9edad",
        "contentType": "STORY",
        "title": "Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting. Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5%...",
        "pubDate": "2026-02-19T01:15:49Z",
        "displayTime": "2026-02-19T01:15:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]